The current strategy involves HLA-DQ compatible haplotypes and tTG-IgA testing once every 2-3 years. The future strategy includes risk stratification into high, medium, low, and none categories, with corresponding annual, every 2-3 years, every 5-10 years, and no screening recommendations respectively.